https://youtu.be/7FlVXYGthUQ
For veterans, mental-health advocates, and healthcare innovators — this New to The Street interview features Dr. Jonathan Javitt, CEO of NRx Pharmaceuticals, and Anne Dunsmore, Founder of Angel Force USA, discussing their joint mission to prevent veteran suicide through advanced neuroplastic therapies and nationwide awareness programs.
Dr. Javitt explains how Hope Therapeutics is developing and deploying treatments that stimulate the brain to form new cells and new neural pathways — including ketamine, cycloserine, and transcranial magnetic stimulation (TMS), all supported by emerging scientific data showing rapid reversal of PTSD and suicidality in veterans. He emphasizes that many legacy antidepressants carry black-box suicide warnings, making alternative neuroplastic therapies urgently needed.
Anne Dunsmore highlights that 22 to 45 veterans and active-duty personnel die by suicide each day, noting that each suicide devastates an estimated 135 lives. She outlines their December Veteran Suicide Summit in Las Vegas — a major event designed to educate, engage, and empower service members, caregivers, and families to recognize risk factors, talk openly, and access life-saving treatments.
Together, NRx and Angel Force USA are building the first integrated model combining FDA-approved devices, novel neuroplastics, digital therapeutics, and veteran-centered care — all focused on achieving what they call the “pathway to zero” suicides.